Dysfunction of either the right or left ventricle can lead to heart failure (HF) and subsequent
morbidity and mortality. We performed a genome-wide association study (GWAS) of 16 …

Recent therapeutic advances have significantly improved the short-and long-term survival
rates in patients with heart disease and cancer. Survival in cancer patients may, however, be …

Chemotherapy and targeted therapies have significantly improved the prognosis of
oncology patients. However, these antineoplastic treatments may also induce adverse …

Oncology has seen growing use of newly developed targeted therapies. Although this has
resulted in dramatic improvements in progression-free and overall survival, challenges in …

Heart failure (HF) and cancer are the leading causes of death worldwide and accumulating
evidence demonstrates that HF and cancer affect one another in a bidirectional way …

Cardiotoxicity, defined as toxicity that affects the heart, is one of the most common adverse
drug effects. Numerous drugs have been shown to have the potential to induce lethal …

Increased awareness of the cardiovascular toxic effects of chemotherapy has led to the
emergence of cardio-oncology (or onco-cardiology), which focuses on screening, monitoring …

Heart failure is a leading cause of cardiovascular morbidity and mortality. However, the
contribution of common genetic variation to heart failure risk has not been fully elucidated …

Several anticancer agents have been associated with cardiac toxic effects. The currently
proposed mechanisms to explain cardiotoxicity differ among anticancer agents, but in fact …

Cardiovascular diseases and cancer remain the leading cause of death worldwide. Despite
the fact that these two conditions have long been considered as distinct clinical entities …